[The efficacy of using thymalin and plasmapheresis in the combined treatment of patients with chronic lympholeukemia].
Results are submitted of study of the effectiveness of inclusion into the treatment program for patients with chronic lymphoid leukemia of specific (thymalin) and unspecific (plasmapheresis) means and modes of immune correction, which made for more rapid attaining clinical and hematological compensation by comparison with chemotherapeutic agents only. Furthermore, the method of combined use of drugs, attempted for the first time, permitted the functional activity of the lymphoid system to be improved, with the clinical and hematological compensation being achieved in a shorter space of time.
N N
NN
Tretiak
T F
TF
Babenko
S N
SN
Gaĭdukova
A S
AS
Zverkova
S P
SP
Beschastnaia
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002699:Chlorambucil / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D013951:Thymus Hormones / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating; D013951:Thymus Hormones; D002699:Chlorambucil; C032805:thymalin; D003520:Cyclophosphamide